|

Dabrafenib+Trametinib Clinical Trials

6 actively recruiting trials

Also known as: Tafinlanr+Mekinist

Pipeline

Phase 2: 5

Top Sponsors

West China Hospital1
Sun Yat-sen University1
Saint Petersburg State University, Russia1
Leiden University Medical Center1
Intergruppo Melanoma Italiano1

Indications

Cancer6
Anaplastic Thyroid Cancer2
Fertility1
Locally Advanced Thyroid Gland Carcinoma1
Mutation1

Other6 trials

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

Phase 2

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)

Phase 2

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

Phase 2

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

Phase 2

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.